FDA Approves Genentech's Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Core Insights - The U.S. FDA has approved Genentech's CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab-axgb) as a subcutaneous formulation for treating adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy [1] Company Summary - Genentech is a member of the Roche Group and has received FDA approval for a new treatment option targeting a specific patient population [1] Industry Summary - The approval is based on results from the Phase I/II GO29781 study, indicating a significant advancement in the treatment landscape for follicular lymphoma [1]